IKT — INHIBIKASE THERAPEUTICS INC

Ownership history in CAXTON CORP  ·  7 quarters on record

This page tracks every 13F SEC filing in which CAXTON CORP reported a position in INHIBIKASE THERAPEUTICS INC (IKT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.36% (2012 Q4)
Avg. % of fund
0.79%
First filed
2012 Q4
Last filed
2025 Q4
Quarters held
7
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 28,453 +12,060 +73.6% 1.36% $58K $2.05
2025 Q3 UNCHANGED 16,393 — 0% 0.12% $27K $1.62
2025 Q2 UNCHANGED 16,393 — 0% 0.32% $32K $1.95
2025 Q1 UNCHANGED 16,393 — 0% 0.71% $35.9M $2.19
3 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    IKT price (monthly, adj. close)

Other funds also holding IKT

As of 2025 Q4 — sorted by position size

Sands Capital Alternatives, LLC 3Y 5.15% Stonepine Capital Management, LLC 3Y 7Y 3.51% Saturn V Capital Management LP 3Y 1.45% Fairmount Funds Management LLC 3Y 1.35% ADAR1 Capital Management, LLC 1.2% Seven Fleet Capital Management LP 0.83% Soleus Capital Management, L.P. 3Y 0.82% Commodore Capital LP 3Y 0.74% Exome Asset Management LLC 0.59% Siren, L.L.C. 0.36%
← Back to CAXTON CORP Holdings